{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:01:31Z","timestamp":1790650891363,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1053\/j.seminhematol.2024.02.002","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T10:12:52Z","timestamp":1709287972000},"page":"83-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prognostication in chronic lymphocytic leukemia"],"prefix":"10.1053","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7393-1138","authenticated-orcid":false,"given":"Riccardo","family":"Moia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10129","key":"10.1053\/j.seminhematol.2024.02.002_bib0001","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.02.002_bib0002","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/asheducation-2017.1.329","article-title":"The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment","volume":"2017","author":"Gaidano","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.02.002_bib0003","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.02.002_bib0004","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.02.002_bib0005","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.02.002_bib0006","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1080\/10428194.2016.1250264","article-title":"Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia","volume":"58","author":"Rossi","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2024.02.002_bib0007","unstructured":"Chronic Lymphocytic Leukemia-Cancer Stat Facts. Surveillance, Epidemiology, and End Results Program. https:\/\/seercancergov\/statfacts\/html\/clylhtml [accessed 10.07.23]"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.02.002_bib0008","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.02.002_bib0009","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199805213382104","article-title":"Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on chronic lymphocytic leukemia","volume":"338","author":"Dighiero","year":"1998","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.02.002_bib0010","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/leu.2017.246","article-title":"Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group","volume":"31","author":"Hoechstetter","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.02.002_bib0011","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41375-020-0747-7","article-title":"Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial","volume":"34","author":"Herling","year":"2020","journal-title":"Leukemia"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.02.002_bib0012","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2019003453","article-title":"International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia","volume":"135","author":"Condoluci","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.02.002_bib0013","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3324\/haematol.2019.228171","article-title":"A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia","volume":"105","author":"Cohen","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.02.002_bib0014","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.02.002_bib0015","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/ajh.24493","article-title":"The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients","volume":"91","author":"Molica","year":"2016","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.02.002_bib0016","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/s41375-021-01149-w","article-title":"Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients","volume":"35","author":"Baumann","year":"2021","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.02.002_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.684621","article-title":"Lymphocyte doubling time as a key prognostic factor to predict time to first treatment in early-stage chronic lymphocytic leukemia","volume":"11","author":"Morabito","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.02.002_bib0018","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/bjh.19052","article-title":"XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling","volume":"203","author":"Moia","year":"2023","journal-title":"Br J Haematol."},{"issue":"16","key":"10.1053\/j.seminhematol.2024.02.002_bib0019","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","article-title":"Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia","volume":"126","author":"Rossi","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.02.002_bib0020","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bjh.16434","article-title":"Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations","volume":"189","author":"Raponi","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.02.002_bib0021","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.02.002_bib0022","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.02.002_bib0023","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hon.3080","article-title":"Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia","volume":"41","author":"Moia","year":"2023","journal-title":"Hematol Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.02.002_bib0024","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"10232","key":"10.1053\/j.seminhematol.2024.02.002_bib0025","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.02.002_bib0026","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.02.002_bib0027","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.02.002_bib0028","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMc2005943","article-title":"Ibrutinib for chronic lymphocytic leukemia with TP53 alterations","volume":"383","author":"Ahn","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.02.002_bib0029","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.02.002_bib0030","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.02.002_bib0031","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1158\/1078-0432.CCR-20-4890","article-title":"Clinical outcomes in patients with multi-hit TP53 chronic lymphocytic leukemia treated with ibrutinib","volume":"27","author":"Brieghel","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.02.002_bib0032","doi-asserted-by":"crossref","first-page":"E306","DOI":"10.1002\/ajh.26235","article-title":"TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases","volume":"96","author":"Morabito","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.02.002_bib0033","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41375-023-01845-9","article-title":"Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study","volume":"37","author":"Bomben","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.02.002_bib0034","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood-2016-01-691550","article-title":"Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy","volume":"128","author":"Herling","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.02.002_bib0035","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ajh.23668","article-title":"Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients","volume":"89","author":"Fo\u00e0","year":"2014","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.02.002_bib0036","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.02.002_bib0037","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1182\/blood.2021011883","article-title":"Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study","volume":"138","author":"Rigolin","year":"2021","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.02.002_bib0038","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/cncr.29566","article-title":"Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens","volume":"121","author":"Thompson","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.02.002_bib0039","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2007-05-092486","article-title":"Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia","volume":"111","author":"Gattei","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.02.002_bib0040","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2007.06965.x","article-title":"CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential","volume":"140","author":"Shanafelt","year":"2008","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.02.002_bib0041","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","article-title":"CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia","volume":"32","author":"Bulian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.02.002_bib0042","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1600-065X.1997.tb00963.x","article-title":"Germinal center development","volume":"156","author":"Liu","year":"1997","journal-title":"Immunol Rev"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.02.002_bib0043","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.02.002_bib0044","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3324\/haematol.2014.119123","article-title":"The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia","volume":"100","author":"Wiestner","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.02.002_bib0045","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1084\/jem.20171288","article-title":"Functional and clinical relevance of VLA-4 (CD49d\/CD29) in ibrutinib-treated chronic lymphocytic leukemia","volume":"215","author":"Tissino","year":"2018","journal-title":"J Exp Med"},{"issue":"18","key":"10.1053\/j.seminhematol.2024.02.002_bib0046","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1158\/1078-0432.CCR-22-3217","article-title":"CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy","volume":"29","author":"Alsadhan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.02.002_bib0047","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.20.00979","article-title":"Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model","volume":"39","author":"Ahn","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.02.002_bib0048","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat Commun"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.02.002_bib0049","doi-asserted-by":"crossref","first-page":"E168","DOI":"10.1002\/ajh.26127","article-title":"Assessment of the 4-factor score: retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study","volume":"96","author":"Morabito","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.02.002_bib0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41375-020-0833-x","article-title":"Survival risk score for real-life relapsed\/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study","volume":"35","author":"Gentile","year":"2021","journal-title":"Leukemia"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.02.002_bib0051","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.02.002_bib0052","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.02.002_bib0053","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.02.002_bib0054","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.02.002_bib0055","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.02.002_bib0056","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/bjh.17502","article-title":"Screening and monitoring of the BTK(C481S) mutation in a real-world cohort of patients with relapsed\/refractory chronic lymphocytic leukaemia during ibrutinib therapy","volume":"194","author":"B\u00f6d\u00f6r","year":"2021","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.02.002_bib0057","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.02.002_bib0058","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","article-title":"BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib","volume":"7","author":"Bonfiglio","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.02.002_bib0059","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3324\/haematol.2019.219550","article-title":"Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia","volume":"105","author":"Diop","year":"2020","journal-title":"Haematologica"},{"issue":"10277","key":"10.1053\/j.seminhematol.2024.02.002_bib0060","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.02.002_bib0061","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.02.002_bib0062","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.02.002_bib0063","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/17474086.2018.1456332","article-title":"Potential of BCL2 as a target for chronic lymphocytic leukemia treatment","volume":"11","author":"Moia","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"36","key":"10.1053\/j.seminhematol.2024.02.002_bib0064","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.02.002_bib0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med."},{"issue":"19","key":"10.1053\/j.seminhematol.2024.02.002_bib0066","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2024.02.002_bib0067","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study","volume":"7","author":"Al-Sawaf","year":"2023","journal-title":"Hemasphere."},{"issue":"1","key":"10.1053\/j.seminhematol.2024.02.002_bib0068","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.02.002_bib0069","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.02.002_bib0070","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/blood.2019003451","article-title":"High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia","volume":"135","author":"Al-Sawaf","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.02.002_bib0071","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/hon.3199","article-title":"Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study","volume":"41","author":"Autore","year":"2023","journal-title":"Hematol Oncol."},{"issue":"2","key":"10.1053\/j.seminhematol.2024.02.002_bib0072","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-021-00429-z","article-title":"Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication","volume":"11","author":"Lu","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.02.002_bib0073","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.02.002_bib0074","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"issue":"S2","key":"10.1053\/j.seminhematol.2024.02.002_bib0075","doi-asserted-by":"crossref","DOI":"10.1002\/hon.30_2879","article-title":"Genetic markers and outcome with front line obinutuzumab plus either chlorambucil or venetoclax\u2014updated analysis of the CLL14 trial","volume":"39","author":"Tausch","year":"2021","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.02.002_bib0076","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.02.002_bib0077","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.02.002_bib0078","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1158\/1078-0432.CCR-22-2779","article-title":"Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"34","key":"10.1053\/j.seminhematol.2024.02.002_bib0079","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.02.002_bib0080","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1200\/JCO.22.02283","article-title":"Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study","volume":"41","author":"Munir","year":"2023","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.02.002_bib0081","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194644","article-title":"Richter syndrome: from molecular pathogenesis to druggable targets","volume":"14","author":"Mouhssine","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.02.002_bib0082","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J Exp Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.02.002_bib0083","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","article-title":"Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"158","author":"Rossi","year":"2012","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.02.002_bib0084","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/leu.2012.357","article-title":"NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome","volume":"27","author":"Villamor","year":"2013","journal-title":"Leukemia"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.02.002_bib0085","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/bloodadvances.2017007302","article-title":"Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib","volume":"1","author":"Miller","year":"2017","journal-title":"Blood Adv"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.02.002_bib0086","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.02.002_bib0087","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.02.002_bib0088","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7920","key":"10.1053\/j.seminhematol.2024.02.002_bib0089","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41586-022-04906-8","article-title":"Super-enhancer hypermutation alters oncogene expression in B cell lymphoma","volume":"607","author":"Bal","year":"2022","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2024.02.002_bib0090","doi-asserted-by":"crossref","first-page":"14385","DOI":"10.1038\/ncomms14385","article-title":"Small genomic insertions form enhancers that misregulate oncogenes","volume":"8","author":"Abraham","year":"2017","journal-title":"Nat Commun"},{"issue":"6215","key":"10.1053\/j.seminhematol.2024.02.002_bib0091","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1126\/science.1259037","article-title":"Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element","volume":"346","author":"Mansour","year":"2014","journal-title":"Science"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.02.002_bib0092","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.immuni.2014.12.021","article-title":"Enhancer sequence variants and transcription-factor deregulation synergize to construct pathogenic regulatory circuits in B-cell lymphoma","volume":"42","author":"Koues","year":"2015","journal-title":"Immunity"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.02.002_bib0093","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/s41588-022-01211-y","article-title":"Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features","volume":"54","author":"Robbe","year":"2022","journal-title":"Nat Genet"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.02.002_bib0094","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.02.002_bib0095","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"28","key":"10.1053\/j.seminhematol.2024.02.002_bib0096","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.02.002_bib0097","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1164517","article-title":"Liquid biopsy in hematological malignancies: current and future applications","volume":"13","author":"Talotta","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.02.002_bib0098","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/bjh.17718","article-title":"Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma","volume":"195","author":"Moia","year":"2021","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.02.002_bib0099","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1158\/1078-0432.CCR-22-0433","article-title":"Circulating tumor DNA-based MRD assessment in patients with CLL treated with obinutuzumab, acalabrutinib, and venetoclax","volume":"28","author":"F\u00fcrstenau","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.02.002_bib0100","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","article-title":"Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction","volume":"178","author":"Kurtz","year":"2019","journal-title":"Cell"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:36:55Z","timestamp":1718411815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0037196324000386"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.02.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostication in chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}